Form 4: Mersana Director Sells Shares in Day One Merger

Mersana Therapeutics Director David Mott reported the disposition of common stock and stock options following the company's merger with Day One Biopharmaceuticals, effective January 6, 2026.

Summary

• David Mott, a Director of Mersana Therapeutics, Inc., reported changes in his beneficial ownership due to the merger with Day One Biopharmaceuticals, Inc.
• The merger became effective on January 6, 2026, with Mersana Therapeutics, Inc. becoming a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.
• Mott disposed of 23,546 shares of common stock held directly and 383 shares held indirectly through the Mott Trust.
• Shareholders received $25.00 per share in upfront cash and one non-tradeable Contingent Value Right (CVR) per share, potentially worth up to an additional $30.25 per CVR upon achievement of certain milestones.
• Stock options with an exercise price less than $25.00 per share were cashed out for the Offer Price minus their exercise price.
• Stock options with an exercise price equal to or greater than $25.00 per share were cancelled if not exercised by a specified date prior to the merger's effective time.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing shareholders with a defined cash payout and potential upside via CVRs. While out-of-the-money options were cancelled, the overall event represents a structured exit for the company's public shareholders.

Positives

• The merger provides Mersana shareholders with immediate cash consideration of $25.00 per share.
• Shareholders also received Contingent Value Rights (CVRs) offering potential additional payments of up to $30.25 per CVR, providing upside potential based on future milestones.
• The transaction provides liquidity for Mersana shareholders, ending their direct equity ownership in the public entity.

Negatives

• Stock options with exercise prices equal to or greater than the upfront cash consideration ($25.00) were cancelled if not exercised, resulting in no value for those specific options.
• The CVRs are non-tradeable, limiting immediate liquidity for the contingent portion of the consideration.
• Mersana Therapeutics, Inc. has ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc.

Risks

• The contingent value rights (CVRs) are subject to the achievement of specific milestones, meaning the full $30.25 per CVR is not guaranteed.
• The CVRs are non-tradeable, limiting the ability of holders to monetize them before milestones are met or if they are not met.
• The value of the CVRs is dependent on the future performance and strategic decisions of Day One Biopharmaceuticals, Inc. regarding Mersana's assets.

Future Outlook

The successful completion of the merger means Mersana Therapeutics, Inc. is now a wholly-owned subsidiary of Day One Biopharmaceuticals, Inc. The future outlook for former Mersana shareholders holding CVRs depends entirely on the achievement of specified milestones by Day One Biopharmaceuticals.

Industry Context

This merger represents consolidation within the biotechnology or pharmaceutical sector, where larger companies acquire smaller ones, often for their pipeline assets or technology. The use of CVRs is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards, reflecting the inherent uncertainties in drug development.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech mergers is a standard practice, particularly when the acquired company has pipeline assets with uncertain future value. Companies like Pfizer, Bristol Myers Squibb, and Gilead Sciences have utilized CVRs in past acquisitions to incentivize milestone achievements.
• The structure of upfront cash plus CVRs is comparable to deals such as the acquisition of MyoKardia by Bristol Myers Squibb or the acquisition of Acceleron Pharma by Merck, where a portion of the deal value was tied to future clinical or regulatory successes.

Management Changes

Corporate Governance

Related Party Transactions

• The indirect ownership of shares by David Mott through the David Mott Declaration of Trust dated May 31, 2001, as amended (the "Mott Trust"), represents a related party holding that was disposed of as part of the merger.

Stakeholder Impact

• Shareholders: Received upfront cash and CVRs for their shares, ending their direct equity ownership in Mersana.
• Employees: Likely integrated into Day One Biopharmaceuticals, Inc., with potential changes in roles, compensation, and benefits.
• Management/Directors: David Mott, as a director, has disposed of his holdings as part of the merger, indicating a change in his relationship with the former public entity.

Next Steps

• Monitoring the achievement of milestones for the Contingent Value Rights (CVRs) by Day One Biopharmaceuticals, Inc.
• Former Mersana shareholders will receive payments if CVR milestones are met.

Key Dates

Keywords

Mersana Therapeutics, Day One Biopharmaceuticals, Merger, Acquisition, Form 4, Beneficial Ownership, Stock Options, Contingent Value Rights, CVR, Biotechnology, Pharmaceuticals